Intraperitoneal Pretargeted Radioimmunotherapy for Colorectal Peritoneal Carcinomatosis

Peritoneal carcinomatosis (PC) is considered incurable, and more effective therapies are needed. Herein we test the hypothesis that GPA33-directed intracompartmental pretargeted radioimmunotherapy (PRIT) can cure colorectal peritoneal carcinomatosis. Nude mice were implanted intraperitoneally with l...

Full description

Saved in:
Bibliographic Details
Published in:Molecular cancer therapeutics 2022-01, Vol.21 (1), p.125-137
Main Authors: Chandler, Christopher S, Bell, Meghan M, Chung, Sebastian K, Veach, Darren R, Fung, Edward K, Punzalan, Blesida, Burnes Vargas, Daniela, Patel, Mitesh, Xu, Hong, Guo, Hong-Fen, Santich, Brian H, Zanzonico, Pat B, Monette, Sébastien, Nash, Garrett M, Cercek, Andrea, Jungbluth, Achim, Pandit-Taskar, Neeta, Cheung, Nai Kong V, Larson, Steven M, Cheal, Sarah M
Format: Article
Language:English
Subjects:
Animals
Colorectal Neoplasms - drug therapy
Disease Models, Animal
Humans
Mice
Mice, Nude
Peritoneal Neoplasms - drug therapy
Radioimmunotherapy - methods
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Peritoneal carcinomatosis (PC) is considered incurable, and more effective therapies are needed. Herein we test the hypothesis that GPA33-directed intracompartmental pretargeted radioimmunotherapy (PRIT) can cure colorectal peritoneal carcinomatosis. Nude mice were implanted intraperitoneally with luciferase-transduced GPA33-expressing SW1222 cells for aggressive peritoneal carcinomatosis (e.g., resected tumor mass 0.369 ± 0.246 g; = 17 on day 29). For GPA33-PRIT, we administered intraperitoneally a high-affinity anti-GPA33/anti-DOTA bispecific antibody (BsAb), followed by clearing agent (intravenous), and lutetium-177 (Lu-177) or yttrium-86 (Y-86) radiolabeled DOTA-radiohapten (intraperitoneal) for beta/gamma-emitter therapy and PET imaging, respectively. The DOTA-radiohaptens were prepared from -2-(4-aminobenzyl)-1,4,7, 10-tetraazacyclododecane tetraacetic acid chelate (DOTA-Bn). Efficacy and toxicity of single- versus three-cycle therapy were evaluated in mice 26-27 days post-tumor implantation. Single-cycle treatment ([ Lu]LuDOTA-Bn 111 MBq; tumor dose: 4,992 cGy) significantly prolonged median survival (MS) approximately 2-fold to 84.5 days in comparison with controls ( = 0.007). With three-cycle therapy (once weekly, total 333 MBq; tumor dose: 14,975 cGy), 6/8 (75%) survived long-term (MS > 183 days). Furthermore, for these treated long-term survivors, 1 mouse was completely disease free (microscopic "cure") at necropsy; the others showed stabilized disease, which was detectable during PET-CT using [ Y]DOTA-Bn. Treatment controls had MS ranging from 42-52.5 days ( < 0.001) and 19/20 mice succumbed to progressive intraperitoneal disease by 69 days. Multi-cycle GPA33 DOTA-PRIT significantly prolongs survival with reversible myelosuppression and no chronic marrow (929 cGy to blood) or kidney (982 cGy) radiotoxicity, with therapeutic indices of 12 for blood and 12 for kidneys. MTD was not reached.
ISSN:1535-7163
1538-8514
DOI:10.1158/1535-7163.MCT-21-0353